KYTX

Kyverna Therapeutics, Inc. (KYTX) - 10-K Summary

Business Context and Reporting Period

Company: Kyverna Therapeutics, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Kyverna is a late-stage clinical biopharmaceutical company developing cell therapies for autoimmune diseases. Its lead product candidate, mivocabtagene autoleucel (miv-cel/KYV-101), is an autologous, fully human CD19-targeting CAR T-cell therapy designed to deeply deplete B cells to achieve durable, treatment-free remission. The company is currently focused on advancing miv-cel for Stiff Person Syndrome (SPS) and Generalized Myasthenia Gravis (gMG).

Key Financial Metrics (Year Ended Dec 31, 2025)

Material Changes vs. Prior Period

• Increased Net Loss: Net loss increased by 27% to $161.3 million, driven by a 19% increase in total operating expenses.
• R&D Spend Growth: R&D expenses rose by $21.2 million (19%), primarily due to accelerated clinical study activities for SPS and gMG, increased Contract Manufacturing Organization (CMO) costs for BLA preparation, and higher personnel costs.
• Debt Financing: In October 2025, the company entered a Loan and Security Agreement with Oxford Finance LLC for up to $150 million. As of year-end, $25.0 million was drawn, resulting in $0.4 million of interest expense for the year.
• Equity Financing: The company raised approximately $115.9 million in net proceeds from equity issuances in 2025, including an underwritten public offering in December and sales under an At-The-Market (ATM) facility.
• Interest Income Decline: Interest income decreased by 41% to $9.1 million due to lower average cash and investment balances compared to 2024.

Guidance, Outlook, and Management Commentary

• SPS Program (KYSA-8): The company reported positive topline results from its registrational Phase 2 trial in Stiff Person Syndrome, achieving primary and all secondary endpoints with high statistical significance. Management plans to submit a Biologics License Application (BLA) to the FDA in the first half of 2026.
• gMG Program (KYSA-6): Positive interim data was reported from the Phase 2 trial. The company initiated the Phase 3 registrational trial in late 2025, with enrollment ongoing.
• Liquidity Runway: Management expects current cash, cash equivalents, and available-for-sale securities ($279.3 million) to fund operations, the SPS BLA filing, commercial launch preparations, and the gMG Phase 3 trial through 2028.
• Next-Gen Pipeline: The Investigational New Drug (IND) application for KYV-102 (a rapid whole blood manufacturing process) was accepted by the FDA in January 2026. The company is also exploring allogeneic CAR T-cell therapies (KYV-201) via a collaboration with Intellia.
• Risks: Key risks include the uncertainty of regulatory approval, the potential for clinical trial delays, reliance on third-party manufacturers, and the need for additional capital if development timelines extend or costs increase. The company also faces ongoing securities litigation regarding its IPO, though a motion to dismiss was granted in March 2026.

Investor Verification Checklist

• BLA Submission Timing: Verify the company's ability to submit the SPS BLA in H1 2026 as planned, given the complexity of cell therapy manufacturing and regulatory review.
• Cash Burn Rate: Monitor quarterly cash burn to ensure the projected runway into 2028 remains valid, especially as Phase 3 gMG enrollment and commercial readiness activities ramp up.
• Debt Covenants: Review the terms of the Oxford Finance loan, specifically the minimum cash balance covenants and revenue milestones required to avoid acceleration of debt repayment.
• Manufacturing Capacity: Confirm the scalability of CMO partnerships (ElevateBio and Minaris) to support both clinical supply and potential commercial launch volumes.
• Legal Proceedings: Track the status of the securities class action and derivative litigation, noting that while a motion to dismiss was granted, the plaintiff was granted leave to file an amended complaint.